Israel's Kahr Medical Attracts Investments From Sanofi, Others
This article was originally published in PharmAsia News
Executive Summary
Israel's drug maker Kahr Medical is set to receive $1 million investment from Hadasit Bio Holdings, which in turn is getting $2.1 million from French drug-maker Sanofi-Aventis
You may also be interested in...
Finance Watch: Multiple VC Mega-Rounds Fund T-Cell, Hearing, IO, Fibrosis Therapies
Private Company Edition: Immunocore’s $130m round kicked off a series of $100m-plus venture capital deals, including financings for Xilio, Akouos and Pliant. Also, VC investment in cell and gene therapies surged in 2019 and MPM launched two funds with $126 for early cancer research.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.